Cited by 122Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsClinical practice guidelines implementation

The DOI matches its Crossref record; 752 of the 752 references it cites were found in a registry or an index.

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Writing Committee Members, Blumenthal, Roger S., Morris, Pamela B., Gaudino, Mario, Johnson, Heather M., Anderson, Timothy S., Bittner, Vera A., Blankstein, Ron, Brewer, LaPrincess C., Cho, Leslie, de Ferranti, Sarah D., Gianos, Eugenia, Gluckman, Ty J., Gradney, Kristen F., Isiadinso, Ijeoma, Lloyd-Jones, Donald M., Marrs, Joel C., Martin, Seth S., McLain, Kellie H., Mehta, Laxmi S., Mora, Samia, Mulugeta, Wudeneh M., Natarajan, Pradeep, Navar, Ann Marie, Orringer, Carl E., Polonsky, Tamar S., Reynolds, Harmony R., Saseen, Joseph J., Shapiro, Michael D., Soffer, Daniel E., Tynes, Sheila A., Villavaso, Chloé D., Virani, Salim S., Wilkins, John T., Rohatgi, Anand, Kim, Samuel M., Alexander, Karen P., Anderson, Cheryl, Benziger, Catherine P., Dixon, Dave L., Duprez, Daniel, Ferdinand, Keith C., Goldberg, Anne Carol, Joshi, Parag, Knowles, Joshua W., Lavie Jr, Carl (Chip) J., Linderbaum, Jane A., McEvoy, John William, Mehta, Anurag, Merz, C. Noel Bairey, Nambi, Vijay, Orkaby, Ariela R., Peña,, Jessica M., Rosenson, Robert, Ruisinger, Janelle, Sandner, Sigrid E., Schott, Stacey L., Sperling, Laurence (Larry), Stone, Neil J., Toth, Peter, Ware, Adam L., Whelton, Seamus Paul, Young, James·2026·Circulation

DOI 10.1161/cir.0000000000001423

Open this paper in CoChat — free account

Abstract

AIM: The “2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia” retires and replaces the “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.” METHODS: A comprehensive literature search was conducted from October 2024 to December 2024 to identify clinical studies, systematic reviews and meta-analyses, and other evidence conducted on human participants that were published in English from MEDLINE (through PubMed), EMBASE, the Cochrane Library, Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. STRUCTURE: The focus of this clinical practice guideline is to address the evaluation, management, and monitoring of individuals with dyslipidemias, including high blood cholesterol, hypertriglyceridemia, and elevated lipoprotein(a).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/cir.0000000000001423

Cites

752 of 752 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citation
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Self-citation
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
Self-citation
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000066 · Cited by 4,347
Association between Multiple Cardiovascular Risk Factors and Atherosclerosis in Children and Young Adults
Berenson, G. S., Srinivasan, S. R., Bao, W., Newman, W. P., Tracy, R. E., & Wattigney, W. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806043382302 · Cited by 4,032
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437741.48606.98 · Cited by 3,697
Self-citation
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citation
Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts
Estruch, R., Ros, E., Salas-Salvadó, J., Covas, M.-I., Corella, D., Arós, F., Gómez-Gracia, E., Ruiz-Gutiérrez, V., Fiol, M., Lapetra, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800389 · Cited by 3,616
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67667-2 · Cited by 3,284
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups
Detrano, R., Guerci, A. D., Carr, J. J., Bild, D. E., Burke, G., Folsom, A. R., Liu, K., Shea, S., Szklo, M., Bluemke, D. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa072100 · Cited by 2,989
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
(2003) · The Lancet · doi:10.1016/s0140-6736(03)13636-7 · Cited by 2,876
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
Martin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800
Self-citation
Life's essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a presidential advisory from the American Heart Association
Lloyd-Jones, D. M., Allen, N. B., Anderson, C. A. M., Black, T., Brewer, L. C., Foraker, R. E., Grandner, M. A., Lavretsky, H., Perak, A. M., Sharma, G., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001078 · Cited by 2,785
Self-citation
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761
The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in Incidence of Coronary Heart Disease
(1984) · JAMA · doi:10.1001/jama.1984.03340270029025 · Cited by 2,747
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001184 · Cited by 2,208
Self-citation
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report
Kavey, R., Simons-Morton, D., & de Jesus, J. D. (2011) · Pediatrics · doi:10.1542/peds.2009-2107c · Cited by 2,131
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis
Collaborators, C. T. T. (. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60104-x · Cited by 2,081
Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Self-citation
Cholesterol-lowering effects of dietary fiber: a meta-analysis
Brown, L., Rosner, B., Willett, W. W., & Sacks, F. M. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.1.30 · Cited by 1,857
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Self-citation
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Food Insecurity Is Associated with Chronic Disease among Low-Income NHANES Participants
Seligman, H. K., Laraia, B. A., & Kushel, M. (2009) · Journal of Nutrition · doi:10.3945/jn.109.112573 · Cited by 1,739
Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies
Hokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706
Effects of a Mediterranean-Style Diet on Cardiovascular Risk Factors: A Randomized Trial
Estruch, R., Martínez-González, M. Á., Corella, D., Salas-Salvadó, J., Ruiz-Gutiérrez, V., Covas, M. I., Fiol, M., Gómez-Gracia, E., López-Sabater, M. C., Vinyoles, E., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-1-200607040-00004 · Cited by 1,704
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665
Carbohydrate quality and human health: a series of systematic reviews and meta-analyses
Reynolds, A., Mann, J., Cummings, J., Winter, N., Mete, E., & Te Morenga, L. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31809-9 · Cited by 1,630
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease
Triant, V. A., Lee, H., Hadigan, C., & Grinspoon, S. K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2190 · Cited by 1,613
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598
Self-citation
Effects of the amount and intensity of exercise on plasma lipoproteins
Kraus, W. E., Houmard, J. A., Duscha, B. D., Knetzger, K. J., Wharton, M. B., McCartney, J. S., Bales, C. W., Henes, S., Samsa, G. P., Otvos, J. D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020194 · Cited by 1,554
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials
(2015) · The Lancet · doi:10.1016/s0140-6736(14)61368-4 · Cited by 1,536
MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09328-5 · Cited by 1,502
Rosuvastatin in older patients with systolic heart failure
Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706201 · Cited by 1,487
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Silverman, M. G., Ference, B. A., Im, K., Wiviott, S. D., Giugliano, R. P., Grundy, S. M., Braunwald, E., & Sabatine, M. S. (2016) · JAMA · doi:10.1001/jama.2016.13985 · Cited by 1,483
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease
Khera, A. V., Emdin, C. A., Drake, I., Natarajan, P., Bick, A. G., Cook, N. R., Chasman, D. I., Baber, U., Mehran, R., Rader, D. J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605086 · Cited by 1,460
Self-citation
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
Kronenberg, F., Mora, S., Stroes, E. S. G., Ference, B. A., Arsenault, B. J., Berglund, L., Dweck, M. R., Koschinsky, M., Lambert, G., Mach, F., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac361 · Cited by 1,449
Self-citation
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Risk of Incident Diabetes With Intensive-Dose Compared With Moderate-Dose Statin Therapy: A Meta-analysis
Preiss, D. (2011) · JAMA · doi:10.1001/jama.2011.860 · Cited by 1,390
Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association
Sacks, F. M., Lichtenstein, A. H., Wu, J. H. Y., Appel, L. J., Creager, M. A., Kris-Etherton, P. M., Miller, M., Rimm, E. B., Rudel, L. L., Robinson, J. G., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000510 · Cited by 1,386
Self-citation
HIV Infection and the Risk of Acute Myocardial Infarction
Freiberg, M. S., Chang, C.-C. H., Kuller, L. H., Skanderson, M., Lowy, E., Kraemer, K. L., Butt, A. A., Goetz, M. B., Leaf, D. A., Oursler, K. A., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.3728 · Cited by 1,340
Development and validation of the American Heart Association’s PREVENT equations
Khan, S. S., Matsushita, K., Sang, Y., Ballew, S. H., Grams, M. E., Surapaneni, A., Blaha, M. J., Carson, A. P., Chang, A. R., Ciemins, E., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067626 · Cited by 1,234
Self-citation
Dietary Sugars Intake and Cardiovascular Health: A Scientific Statement From the American Heart Association
Johnson, R. K., Appel, L. J., Brands, M., Howard, B. V., Lefevre, M., Lustig, R. H., Sacks, F., Steffen, L. M., & Wylie-Rosett, J. (2009) · Circulation · doi:10.1161/circulationaha.109.192627 · Cited by 1,207
Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis
Lee, C. M. Y., Huxley, R. R., Wildman, R. P., & Woodward, M. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.08.012 · Cited by 1,173
C-reactive protein, fibrinogen, and cardiovascular disease prediction
The Emerging Risk Factors Collaboration (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107477 · Cited by 1,150
Preeclampsia and Future Cardiovascular Health: A Systematic Review and Meta-Analysis
Wu, P., Haththotuwa, R., Kwok, C. S., Babu, A., Kotronias, R. A., Rushton, C., Zaman, A., Fryer, A. A., Kadam, U., Chew-Graham, C. A., et al. (2017) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.003497 · Cited by 1,147
Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals
Yeboah, J., McClelland, R. L., Polonsky, T. S., Burke, G. L., Sibley, C. T., O’Leary, D., Carr, J. J., Goff, D. C., Greenland, P., & Herrington, D. M. (2012) · JAMA · doi:10.1001/jama.2012.9624 · Cited by 1,122
Self-citation
Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology
Nordestgaard, B. G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306249 · Cited by 1,116
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
GISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61240-4 · Cited by 1,106
Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis
Dattilo, A., & Kris-Etherton, P. (1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/56.2.320 · Cited by 1,055
Epidemiology of Heart Failure
Roger, V. L. (2021) · Circulation Research · doi:10.1161/circresaha.121.318172 · Cited by 1,055
Statin use and reduced cancer-related mortality
Nielsen, S. F., Nordestgaard, B. G., & Bojesen, S. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201735 · Cited by 1,030
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk
Nicholls, S. J., Lincoff, A. M., Garcia, M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., et al. (2020) · JAMA · doi:10.1001/jama.2020.22258 · Cited by 1,028
Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study
Ray, J. G., Vermeulen, M. J., Schull, M. J., & Redelmeier, D. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67726-4 · Cited by 1,013
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
Nissen, S. E., Lincoff, A. M., Brennan, D., Ray, K. K., Mason, D., Kastelein, J. J. P., Thompson, P. D., Libby, P., Cho, L., Plutzky, J., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2215024 · Cited by 988
Self-citation
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial
O’Donoghue, M. L., Fazio, S., Giugliano, R. P., Stroes, E. S. G., Kanevsky, E., Gouni-Berthold, I., Im, K., Lira Pineda, A., Wasserman, S. M., Češka, R., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037184 · Cited by 984
Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
Manson, J. E., Cook, N. R., Lee, I.-M., Christen, W., Bassuk, S. S., Mora, S., Gibson, H., Albert, C. M., Gordon, D., Copeland, T., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811403 · Cited by 979
Self-citation
Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV: Systematic Review and Meta-Analysis
Shah, A. S. V., Stelzle, D., Lee, K. K., Beck, E. J., Alam, S., Clifford, S., Longenecker, C. T., Strachan, F., Bagchi, S., Whiteley, W., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033369 · Cited by 975
Standards of Medical Care in Diabetes—2015 Abridged for Primary Care Providers
American Diabetes Association (2015) · Clinical Diabetes · doi:10.2337/diaclin.33.2.97 · Cited by 947
Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia
Khera, A. V., Won, H.-H., Peloso, G. M., Lawson, K. S., Bartz, T. M., Deng, X., van Leeuwen, E. M., Natarajan, P., Emdin, C. A., Bick, A. G., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.520 · Cited by 942
Self-citation
Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial
Nakamura, H., Arakawa, K., Itakura, H., Kitabatake, A., Goto, Y., Toyota, T., Nakaya, N., Nishimoto, S., Muranaka, M., Yamamoto, A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69472-5 · Cited by 941
Molecular genetics of the LDL receptor gene in familial hypercholesterolemia
Hobbs, H. H., Brown, M. S., & Goldstein, J. L. (1992) · Human Mutation · doi:10.1002/humu.1380010602 · Cited by 921
Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease
Ference, B. A., Yoo, W., Alesh, I., Mahajan, N., Mirowska, K. K., Mewada, A., Kahn, J., Afonso, L., Williams, K. A., & Flack, J. M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.017 · Cited by 898
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment
Wiegman, A., Gidding, S. S., Watts, G. F., Chapman, M. J., Ginsberg, H. N., Cuchel, M., Ose, L., Averna, M., Boileau, C., Borén, J., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv157 · Cited by 891
Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Profile
Martin, S. S., Blaha, M. J., Elshazly, M. B., Toth, P. P., Kwiterovich, P. O., Blumenthal, R. S., & Jones, S. R. (2013) · JAMA · doi:10.1001/jama.2013.280532 · Cited by 883
Self-citation
Common variants associated with plasma triglycerides and risk for coronary artery disease
Do, R., Willer, C. J., Schmidt, E. M., Sengupta, S., Gao, C., Peloso, G. M., Gustafsson, S., Kanoni, S., Ganna, A., Chen, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2795 · Cited by 862
Self-citation
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600176 · Cited by 848
Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis
Richardson, T. G., Sanderson, E., Palmer, T. M., Ala-Korpela, M., Ference, B. A., Davey Smith, G., & Holmes, M. V. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003062 · Cited by 843
Parental Cardiovascular Disease as a Risk Factor for Cardiovascular Disease in Middle-aged Adults
Lloyd‐Jones, D. M., Nam, B., D’Agostino, R. B., Levy, D. A., Murabito, J. M., Wang, T. J., Wilson, P. W. F., & O’Donnell, C. J. (2004) · JAMA · doi:10.1001/jama.291.18.2204 · Cited by 833
Self-citation
Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-analysis
Muka, T., Oliver-Williams, C., Kunutsor, S., Laven, J. S. E., Fauser, B. C. J. M., Chowdhury, R., Kavousi, M., & Franco, O. H. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.2415 · Cited by 826
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913805 · Cited by 818
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial
Ridker, P. M., Pradhan, A., MacFadyen, J. G., Libby, P., & Glynn, R. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61190-8 · Cited by 816
Differential Effects of Aerobic Exercise, Resistance Training and Combined Exercise Modalities on Cholesterol and the Lipid Profile: Review, Synthesis and Recommendations
Mann, S., Beedie, C., & Jimenez, A. (2014) · Sports Medicine · doi:10.1007/s40279-013-0110-5 · Cited by 801
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
Armitage, J., Baigent, C., Barnes, E., Betteridge, D. J., Blackwell, L., Blazing, M., Bowman, L., Braunwald, E., Byington, R., Cannon, C., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31942-1 · Cited by 801
Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association
Khan, S. S., Coresh, J., Pencina, M. J., Ndumele, C. E., Rangaswami, J., Chow, S. L., Palaniappan, L. P., Sperling, L. S., Virani, S. S., Ho, J. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001191 · Cited by 797
Self-citation
Twenty Year Trends and Sex Differences in Young Adults Hospitalized With Acute Myocardial Infarction
Arora, S., Stouffer, G. A., Kucharska‐Newton, A., Qamar, A., Vaduganathan, M., Pandey, A., Porterfield, D. S., Blankstein, R., Rosamond, W. D., Bhatt, D. L., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037137 · Cited by 795
Self-citation
Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins: A Meta-analysis
Boekholdt, S. M., Arsenault, B. J., Mora, S., Pedersen, T. R., LaRosa, J. C., Nestel, P. J., Simes, R. J., Durrington, P., Hitman, G. A., Welch, K. M. A., et al. (2012) · JAMA · doi:10.1001/jama.2012.366 · Cited by 795
Self-citation
Evinacumab for Homozygous Familial Hypercholesterolemia
Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004215 · Cited by 793
Self-citation
Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association
Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., II, Goldstein, L. B., Chin, C. C., Tannock, L. R., Miller, M. J., Raghuveer, G., et al. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 790
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
Self-citation
Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials
Bueno, N. B., de Melo, I. S. V., de Oliveira, S. L., & da Rocha Ataide, T. (2013) · British Journal of Nutrition · doi:10.1017/s0007114513000548 · Cited by 778
Ischemia and No Obstructive Coronary Artery Disease (INOCA)
Merz, C. N. B., Pepine, C. J., Walsh, M. N., Fleg, J. L., Camici, P. G., Chilian, W. M., Clayton, J. A., Cooper, L. S., Crea, F., Carli, M. F. D., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024534 · Cited by 778
Self-citation
Statin-Associated Side Effects
Thompson, P. D., Panza, G. A., Zaleski, A. L., & Taylor, B. A. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.071 · Cited by 776
Drug-Induced Acute Liver Failure: Results of a U.S. Multicenter, Prospective Study
Reuben, A., Koch, D. G., & Lee, W. M. (2010) · Hepatology · doi:10.1002/hep.23937 · Cited by 772
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Raal, F. J., Stein, E. A., Dufour, R., Turner, T., Civeira, F., Burgess, L., Langslet, G., Scott, R., Olsson, A. G., Sullivan, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61399-4 · Cited by 756
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210645 · Cited by 749
Mendelian randomization of blood lipids for coronary heart disease
Holmes, M. V., Asselbergs, F. W., Palmer, T. M., Drenos, F., Lanktree, M. B., Nelson, C. P., Dale, C. E., Padmanabhan, S., Finan, C., Swerdlow, D. I., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/eht571 · Cited by 748
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
Raal, F. J., Honarpour, N., Blom, D. J., Hovingh, G. K., Xu, F., Scott, R. C., Wasserman, S. M., & Stein, E. A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61374-x · Cited by 746
Adverse Pregnancy Outcomes and Cardiovascular Disease Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women: A Scientific Statement From the American Heart Association
Parikh, N. I., Gonzalez, J. M., Anderson, C. A. M., Judd, S. E., Rexrode, K. M., Hlatky, M. A., Gunderson, E. P., Stuart, J. J., Vaidya, D., & On behalf of the American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, T. A. V. B. C. O. C. A. S. N. A. T. S. C. (2021) · Circulation · doi:10.1161/cir.0000000000000961 · Cited by 743
Self-citation
Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants
Aragam, K. G., Jiang, T., Goel, A., Kanoni, S., Wolford, B. N., Atri, D. S., Weeks, E. M., Wang, M., Hindy, G., Zhou, W., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01233-6 · Cited by 738
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study
Versmissen, J., Oosterveer, D. M., Yazdanpanah, M., Defesche, J. C., Basart, D. C. G., Liem, A. H., Heeringa, J., Witteman, J. C. M., Lansberg, P. J., Kastelein, J. J. P., et al. (2008) · BMJ · doi:10.1136/bmj.a2423 · Cited by 719
Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials
Mega, J. L., Stitziel, N. O., Smith, J. G., Chasman, D. I., Caulfield, M. J., Devlin, J. J., Nordio, F., Hyde, C. L., Cannon, C. P., Sacks, F. M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61730-x · Cited by 704
Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease
Ference, B. A., Kastelein, J. J. P., Ray, K. K., Ginsberg, H. N., Chapman, M. J., Packard, C. J., Laufs, U., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., et al. (2019) · JAMA · doi:10.1001/jama.2018.20045 · Cited by 703
Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood
Dabelea, D., Stafford, J. M., Mayer-Davis, E. J., D’Agostino, R., Dolan, L., Imperatore, G., Linder, B., Lawrence, J. M., Marcovina, S. M., Mottl, A. K., et al. (2017) · JAMA · doi:10.1001/jama.2017.0686 · Cited by 700
Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804989 · Cited by 698
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis
Athyros, V. G., Tziomalos, K., Gossios, T. D., Griva, T., Anagnostis, P., Kargiotis, K., Pagourelias, E. D., Theocharidou, E., Karagiannis, A., & Mikhailidis, D. P. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61272-x · Cited by 685
Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the Multi-Ethnic Study of Atherosclerosis (MESA)
Budoff, M. J., Young, R., Burke, G., Jeffrey Carr, J., Detrano, R. C., Folsom, A. R., Kronmal, R., Lima, J. A. C., Liu, K. J., McClelland, R. L., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy217 · Cited by 684
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
HPS2-THRIVE Collaborative Group, Haynes, R., Jiang, L., Hopewell, J. C., Li, J., Chen, F., Parish, S., Landray, M. J., Collins, R., Armitage, J., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht055 · Cited by 676
A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk
Sniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.959247 · Cited by 659
Non–High-Density Lipoprotein Cholesterol Level as a Predictor of Cardiovascular Disease Mortality
Cui, Y. A., Blumenthal, R. S., Flaws, J. A., Whiteman, M. K., LANGENBERG, P. W., Bachorik, P. S., & Bush, T. L. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.11.1413 · Cited by 657
Self-citation
20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia
Luirink, I. K., Wiegman, A., Kusters, D. M., Hof, M. H. P., Groothoff, J. W., de Groot, E., Kastelein, J. J. P., & Hutten, B. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816454 · Cited by 655
Childhood Cardiovascular Risk Factors and Adult Cardiovascular Events
Jacobs, D. R., Woo, J. G., Sinaiko, A. R., Daniels, S. R., Ikonen, J., Juonala, M., Kartiosuo, N., Lehtimäki, T. J., Magnussen, C. G., Viikari, J. S. A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109191 · Cited by 652
Efficacy and Safety of Statin Therapy in Children With Familial Hypercholesterolemia
Wiegman, A., Hutten, B. A., de Groot, E., Rodenburg, J., Bakker, H. D., Büller, H. R., Sijbrands, E. J. G., & Kastelein, J. J. P. (2004) · JAMA · doi:10.1001/jama.292.3.331 · Cited by 646
Clinical Genetic Testing for Familial Hypercholesterolemia
Sturm, A. C., Knowles, J. W., Gidding, S. S., Ahmad, Z., Ahmed, C. D., Ballantyne, C. M., Baum, S. J., Bourbon, M., Carrié, A., Cuchel, M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.05.044 · Cited by 643
Self-citation
Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial
Delgado-Lista, J., Alcala-Diaz, J. F., Torres-Peña, J. D., Quintana-Navarro, G. M., Fuentes, F., Garcia-Rios, A., Ortiz-Morales, A. M., Gonzalez-Requero, A. I., Perez-Caballero, A. I., Yubero-Serrano, E. M., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00122-2 · Cited by 642
Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication
Benn, M., Watts, G. F., Tybjaerg-Hansen, A., & Nordestgaard, B. G. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1563 · Cited by 632
Clinical utility of different lipid measures for prediction of coronary heart disease in men and women
Ingelsson, E., Schaefer, E. J., Contois, J. H., McNamara, J. R., Sullivan, L., Keyes, M. J., Pencina, M. J., Schoonmaker, C., Wilson, P. W. F., D’Agostino, R. B., et al. (2007) · JAMA · doi:10.1001/jama.298.7.776 · Cited by 608
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Sabatine, M. S., Leiter, L. A., Wiviott, S. D., Giugliano, R. P., Deedwania, P., De Ferrari, G. M., Murphy, S. A., Kuder, J. F., Gouni-Berthold, I., Lewis, B. S., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30313-3 · Cited by 603
A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia
Sampson, M. L., Ling, C., Sun, Q., Harb, R., Ashmaig, M., Warnick, R., Sethi, A. A., Fleming, J. K., Otvos, J. D., Meeusen, J. W., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0013 · Cited by 593
Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data
Zhu, D., Chung, H., Dobson, A. J., Pandeya, N., Giles, G. G., Bruinsma, F., Brunner, E. J., Kuh, D. J., Hardy, R., Avis, N. E., et al. (2019) · The Lancet Public Health · doi:10.1016/s2468-2667(19)30155-0 · Cited by 589
Fasting and Nonfasting Lipid Levels: Influence of Normal Food Intake on Lipids, Lipoproteins, Apolipoproteins, and Cardiovascular Risk Prediction
Langsted, A., Freiberg, J. J., & Nordestgaard, B. G. (2008) · Circulation · doi:10.1161/circulationaha.108.804146 · Cited by 588
Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis
Yu-Poth, S., Zhao, G., Etherton, T., Naglak, M., Jonnalagadda, S., & Kris-Etherton, P. M. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.4.632 · Cited by 584
Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease
Hu, P., Dharmayat, K., Stevens, C. A. T., Sharabiani, M. T. A., Jones, R., Watts, G. F., Genest, J. J., Ray, K. K., & Vallejo‐Vaz, A. J. (2020) · Circulation · doi:10.1161/circulationaha.119.044795 · Cited by 583
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Bittner, V. A., Szarek, M., Aylward, P. E., Bhatt, D. L., Diaz, R., Edelberg, J. M., Fras, Z., Goodman, S. G., Halvorsen, S., Hanotin, C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.057 · Cited by 572
Self-citation
Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting
Natarajan, P., Young, R., Stitziel, N. O., Padmanabhan, S., Baber, U., Mehran, R., Sartori, S., Fuster, V., Reilly, D. F., Butterworth, A., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024436 · Cited by 570
Self-citation
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Lloyd-Jones, D. M., Morris, P. B., Ballantyne, C. M., Birtcher, K. K., Covington, A. M., DePalma, S. M., Minissian, M. B., Orringer, C. E., Smith, S. C., Waring, A. A., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.07.006 · Cited by 569
Self-citation
Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank
Patel, A. P., Wang, M., Pirruccello, J. P., Ellinor, P. T., Ng, K., Kathiresan, S., & Khera, A. V. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.315291 · Cited by 567
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Willeit, P., Ridker, P. M., Nestel, P. J., Simes, J., Tonkin, A. M., Pedersen, T. R., Schwartz, G. G., Olsson, A. G., Colhoun, H. M., Kronenberg, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31652-0 · Cited by 564
Self-citation
Atherosclerotic Cardiovascular Disease in South Asians in the United States: Epidemiology, Risk Factors, and Treatments: A Scientific Statement From the American Heart Association
Volgman, A. S., Palaniappan, L. S., Aggarwal, N. T., Gupta, M., Khandelwal, A., Krishnan, A. V., Lichtman, J. H., Mehta, L. S., Patel, H. N., Shah, K. S., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000580 · Cited by 552
Self-citation
Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes
Knopp, R. H., d’Emden, M., Smilde, J. G., Pocock, S. J., & on behalf of the ASPEN Study Group (2006) · Diabetes Care · doi:10.2337/dc05-2415 · Cited by 550
Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis
Navarese, E. P., Robinson, J. G., Kowalewski, M., Kolodziejczak, M., Andreotti, F., Bliden, K., Tantry, U., Kubica, J., Raggi, P., & Gurbel, P. A. (2018) · JAMA · doi:10.1001/jama.2018.2525 · Cited by 549
DASH Dietary Pattern and Cardiometabolic Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses
Chiavaroli, L., Viguiliouk, E., Nishi, S., Blanco Mejia, S., Rahelić, D., Kahleová, H., Salas-Salvadó, J., Kendall, C., & Sievenpiper, J. (2019) · Nutrients · doi:10.3390/nu11020338 · Cited by 548
Pitavastatin to Prevent Cardiovascular Disease in HIV Infection
Grinspoon, S. K., Fitch, K. V., Zanni, M. V., Fichtenbaum, C. J., Umbleja, T., Aberg, J. A., Overton, E. T., Malvestutto, C., Bloomfield, G. S., Currier, J. S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304146 · Cited by 532
Carbohydrate-induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms
Parks, E. J., & Hellerstein, M. K. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.2.412 · Cited by 530
Menstrual cycle irregularity and risk for future cardiovascular disease
Solomon, C. G., Hu, F. B., Dunaif, A., Rich-Edwards, J. E., Stampfer, M. J., Willett, W. C., Speizer, F. E., & Manson, J. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.5.8471 · Cited by 528
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial
Nissen, S. E., Stroes, E., Dent-Acosta, R. E., Rosenson, R. S., Lehman, S. J., Sattar, N., Preiss, D., Bruckert, E., Ceška, R., Lepor, N., et al. (2016) · JAMA · doi:10.1001/jama.2016.3608 · Cited by 522
Self-citation
Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men
Pischon, T., Girman, C. J., Sacks, F. M., Rifai, N., Stampfer, M. J., & Rimm, E. B. (2005) · Circulation · doi:10.1161/circulationaha.104.532499 · Cited by 514
Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association
Skulas-Ray, A. C., Wilson, P. W. F., Harris, W. S., Brinton, E. A., Kris-Etherton, P. M., Richter, C. K., Jacobson, T. A., Engler, M. B., Miller, M., Robinson, J. G., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000709 · Cited by 512
Safety and Benefit of Discontinuing Statin Therapy in the Setting of Advanced, Life-Limiting Illness: A Randomized Clinical Trial
Kutner, J. S., Blatchford, P. J., Taylor, D. H., Ritchie, C. S., Bull, J. H., Fairclough, D. L., Hanson, L. C., LeBlanc, T. W., Samsa, G. P., Wolf, S., et al. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.0289 · Cited by 502
The 30-Year Natural History of Type 1 Diabetes Complications
Pambianco, G., Costacou, T., Ellis, D., Becker, D. J., Klein, R., & Orchard, T. J. (2006) · Diabetes · doi:10.2337/db05-1423 · Cited by 501
Effect of statins on skeletal muscle function
Parker, B. A., Capizzi, J. A., Grimaldi, A. S., Clarkson, P. M., Cole, S. M., Keadle, J., Chipkin, S., Pescatello, L. S., Simpson, K., White, C. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.136101 · Cited by 500
2016 SCCT/STR guidelines for coronary artery calcium scoring of noncontrast noncardiac chest CT scans: a report of the Society of Cardiovascular Computed Tomography and Society of Thoracic Radiology
Hecht, H. S., Cronin, P., Blaha, M. J., Budoff, M. J., Kazerooni, E. A., Narula, J., Yankelevitz, D., & Abbara, S. (2017) · Journal of Cardiovascular Computed Tomography · doi:10.1016/j.jcct.2016.11.003 · Cited by 492
Targeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women.
Mora, S., Otvos, J. D., Rifai, N., Rosenson, R. S., Buring, J. E., & Ridker, P. M. (2009) · Circulation · doi:10.1161/circulationaha.108.816181 · Cited by 490
Self-citation
Implications of Coronary Artery Calcium Testing Among Statin Candidates According to American College of Cardiology/American Heart Association Cholesterol Management Guidelines
Nasir, K., Bittencourt, M. S., Blaha, M. J., Blankstein, R., Agatson, A. S., Rivera, J. J., Miedema, M. D., Sibley, C. T., Shaw, L. J., Blumenthal, R. S., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.066 · Cited by 488
Self-citation
Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands
Umans-Eckenhausen, M. A. W., Defesche, J. C., Sijbrands, E. J. G., Scheerder, R. L. J. M., & Kastelein, J. J. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03587-x · Cited by 488
Multimorbidity in Older Adults With Cardiovascular Disease
Forman, D. E., Maurer, M. S., Boyd, C., Brindis, R., Salive, M. E., Horne, F. M., Bell, S. P., Fulmer, T., Reuben, D. B., Zieman, S., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.022 · Cited by 484
Prevalence of statin intolerance: a meta-analysis
Bytyçi, I., Penson, P. E., Mikhailidis, D. P., Wong, N. D., Hernandez, A. V., Sahebkar, A., Thompson, P. D., Mazidi, M., Rysz, J., Pella, D., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac015 · Cited by 481
Self-citation
Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Davidson, K. W., Barry, M. J., Mangione, C. M., Cabana, M., Caughey, A. B., Davis, E. M., Donahue, K. E., Doubeni, C. A., Krist, A. H., et al. (2021) · JAMA · doi:10.1001/jama.2021.12531 · Cited by 480
Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia
Gagné, C., Gaudet, D., & Bruckert, É. (2002) · Circulation · doi:10.1161/01.cir.0000018744.58460.62 · Cited by 480
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
Kastelein, J. J. P., van der Steeg, W. A., Holme, I., Gaffney, M., Cater, N. B., Barter, P., Deedwania, P., Olsson, A. G., Boekholdt, S. M., Demicco, D. A., et al. (2008) · Circulation · doi:10.1161/circulationaha.107.713438 · Cited by 478
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment
LEE, E., RYAN, S., Birmingham, B. K., Zalikowski, J. A., March, R. E., Ambrose, H., MOORE, R., Lee, C. G. L., CHEN, Y., & Schneck, D. W. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.013 · Cited by 476
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
Moriarty, P. M., Thompson, P. D., Cannon, C. P., Guyton, J. R., Bergeron, J., Zieve, F. J., Bruckert, E., Jacobson, T. A., Kopecky, S. L., Baccara-Dinet, M. T., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.08.006 · Cited by 470
Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association
de Ferranti, S. D., Steinberger, J., Ameduri, R. K., Baker, A., Gooding, H. C., Kelly, A. S., Mietus‐Snyder, M., Mitsnefes, M. M., Peterson, A. L. H., St‐Pierre, J., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000618 · Cited by 464
Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
Khera, A. V., Everett, B. M., Caulfield, M. P., Hantash, F. M., Wohlgemuth, J., Ridker, P. M., & Mora, S. (2014) · Circulation · doi:10.1161/circulationaha.113.004406 · Cited by 461
Self-citation
Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK
Conrad, N., Verbeke, G. N., Molenberghs, G., Goetschalckx, L., Callender, T., Cambridge, G., Mason, J. C., Rahimi, K., McMurray, J. J. V., & Verbakel, J. Y. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01349-6 · Cited by 457
Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy
McCowan, L. M., Figueras, F., & Anderson, N. H. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.12.004 · Cited by 451
Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events
Mora, S., Rifai, N., Buring, J. E., & Ridker, P. M. (2008) · Circulation · doi:10.1161/circulationaha.108.777334 · Cited by 445
Self-citation
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity
Chalasani, N., Aljadhey, H., Kesterson, J., Murray, M. D., & Hall, S. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.015 · Cited by 441
Effects of aerobic exercise on lipids and lipoproteins
Wang, Y., & Xu, D. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0515-5 · Cited by 436
Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
Laufs, U., Banach, M., Mancini, G. B. J., Gaudet, D., Bloedon, L. T., Sterling, L. R., Kelly, S., & Stroes, E. S. G. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011662 · Cited by 432
Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population
Bergström, G. M. L., Persson, M., Adiels, M., Björnson, E., Bonander, C., Ahlström, H. K., Alfredsson, J., Angerås, O., Berglund, G. L., Blomberg, A., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.055340 · Cited by 431
Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications
Martin, S. S., Blaha, M. J., Elshazly, M. B., Brinton, E. A., Toth, P. P., McEvoy, J. W., Joshi, P. H., Kulkarni, K. R., Mize, P. D., Kwiterovich, P. O., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.079 · Cited by 428
Self-citation
Status of Cardiovascular Disease and Stroke in Hispanics/Latinos in the United States: A Science Advisory From the American Heart Association
Rodriguez, C. J., Allison, M., Daviglus, M. L., Isasi, C. R., Keller, C., Leira, E. C., Palaniappan, L., Piña, I. L., Ramirez, S. M., Rodriguez, B., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000071 · Cited by 426
Genetic identification of familial hypercholesterolemia within a single U.S. health care system
Abul-Husn, N. S., Manickam, K., Jones, L. K., Wright, E. A., Hartzel, D. N., Gonzaga-Jauregui, C., O’Dushlaine, C., Leader, J. B., Lester Kirchner, H., Lindbuchler, D. M., et al. (2016) · Science · doi:10.1126/science.aaf7000 · Cited by 425
Long-Term Complications and Mortality in Young-Onset Diabetes
Constantino, M. I., Molyneaux, L., Limacher-Gisler, F., Al-Saeed, A., Luo, C., Wu, T., Twigg, S. M., Yue, D. K., & Wong, J. (2013) · Diabetes Care · doi:10.2337/dc12-2455 · Cited by 423
Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
Ballantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.002 · Cited by 422
Associations of Coronary Heart Disease Risk Factors With the Intermediate Lesion of Atherosclerosis in Youth
McGill, H. C., McMahan, C. A., Zieske, A. W., Sloop, G. D., Walcott, J. V., Troxclair, D. A., Malcom, G. T., Tracy, R. E., Oalmann, M. C., & Strong, J. P. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.8.1998 · Cited by 421
Treatment of Asymptomatic Adults With Elevated Coronary Calcium Scores With Atorvastatin, Vitamin C, and Vitamin E
Arad, Y., Spadaro, L. A., Roth, M., Newstein, D., & Guerci, A. D. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.089 · Cited by 414
Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217
Benn, M., Watts, G. F., Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw028 · Cited by 414
National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement
Bachorik, P. S., & Ross, J. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.10.1414 · Cited by 412
Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease
Navar‐Boggan, A. M., Peterson, E. D., D’Agostino, R. B., Neely, B., Sniderman, A. D., & Pencina, M. J. (2015) · Circulation · doi:10.1161/circulationaha.114.012477 · Cited by 412
Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk
Domanski, M. J., Tian, X., Wu, C. O., Reis, J. P., Dey, A. K., Gu, Y., Zhao, L., Bae, S., Liu, K., Hasan, A. A., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.07.059 · Cited by 411
Self-citation
Long-term evolocumab in patients with established atherosclerotic cardiovascular disease
O’Donoghue, M. L., Giugliano, R. P., Wiviott, S. D., Atar, D., Keech, A., Kuder, J. F., Im, K., Murphy, S. A., Flores-Arredondo, J. H., López, J. A. G., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.061620 · Cited by 410
Navigating the Crossroads of Coronary Artery Disease and Heart Failure
Gheorghiade, M., Sopko, G. S., Luca, L. D., Velazquez, E. J., Parker, J. D., Binkley, P. F., Sadowski, Z., Golba, K. S., Prior, D., Rouleau, J. L., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.623199 · Cited by 408
Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both
Ference, B. A., Majeed, F., Penumetcha, R., Flack, J. M., & Brook, R. D. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.020 · Cited by 407
Routine assessment and promotion of physical activity in healthcare settings: A scientific statement from the American Heart Association
Lobelo, F., Rohm Young, D., Sallis, R., Garber, M. D., Billinger, S. A., Duperly, J., Hutber, A., Pate, R. R., Thomas, R. J., Widlansky, M. E., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000559 · Cited by 402
High Risk of Cardiovascular Disease in Patients With Type 1 Diabetes in the U.K.
Soedamah‐Muthu, S. S., Fuller, J., Mulnier, H. E., Raleigh, V. S., Lawrenson, R. A., & Colhoun, H. M. (2006) · Diabetes Care · doi:10.2337/diacare.29.04.06.dc05-1433 · Cited by 395
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance
Cuchel, M., Raal, F. J., Hegele, R. A., Al‐Rasadi, K., Arca, M., Averna, M. R., Bruckert, É., Freiberger, T., Gaudet, D., Harada‐Shiba, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad197 · Cited by 393

Research works printed but not linked: 243

Kazi DS, Abdullah AR, Arnold SV, et al. 2025 AHA/ACC statement on cost/value methodology in clinical practice guidelines (update from 2014 statement): a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;151:e332–e358.
Otto CM, Abdullah AR, Davis LL, et al. 2025 ACC/AHA guideline core principles and development process: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;152:e359–e370.
Jneid H, Abdullah AR, Ferrari V, et al. Guidance for incorporating FDA processes into the ACC/AHA clinical practice guideline methodology: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;152:e323–e331.
Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2019;2019(11):CD006401.
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128 Suppl 5:S213–S256.
Centers for Disease Control and Prevention (CDC). Prevalence of abnormal lipid levels among youths-United States, 1999-2006. MMWR Morb Mortal Wkly Rep. 2010;59:29–33.
10.1016/S0140-6736(19)32519-X · DOI
10.1161/CIR.0000000000000625 · DOI · Paper page
10.1161/CIRCULATIONAHA.119.041149 · DOI · Paper page
MacDougall DE, Tybjaerg-Hansen A, Knowles JW, et al. Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database. Eur Heart J. 2025;ehaf297.
10.1056/NEJMoa1812792 · DOI · Paper page
10.1056/NEJMoa1615664 · DOI · Paper page
10.1056/NEJMoa2215024 · DOI · Paper page
10.1161/CIR.0000000000001078 · DOI · Paper page
10.1161/CIR.0000000000000678 · DOI · Paper page
10.1056/NEJMoa2109191 · DOI
10.1056/NEJMoa1800389 · DOI · Paper page
10.1161/CIR.0000000000000678 · DOI · Paper page
10.1161/CIR.0000000000000625 · DOI · Paper page
10.1016/j.jacc.2021.06.011 · DOI · Paper page
10.1210/clinem/dgaa673 · DOI · Paper page
10.1093/eurheartj/ehad211 · DOI
10.1161/CIR.0000000000000678 · DOI · Paper page
10.1111/j.1467-789X.2012.01021.x · DOI · Paper page
10.1016/j.jacl.2023.05.099 · DOI
10.1093/ajcn/56.2.320 · DOI · Paper page
10.1161/CIR.0000000000001078 · DOI · Paper page
10.1007/s40279-024-02115-z · DOI · Paper page
10.1056/NEJMoa020194 · DOI · Paper page
Li Y, Zhai Q, Li G, et al. Effects of different aerobic exercises on blood lipid levels in middle-aged and elderly people: a systematic review and bayesian network meta-analysis based on randomized controlled trials. Healthcare (Basel). 2024;12:1309.
10.1161/CIR.0b013e3182160726 · DOI · Paper page
US Department of Health and Human Services. Physical Activity Guidelines for Americans. 2nd edition. US Department of Health and Human Services; 2018.
10.1056/NEJMoa1410489 · DOI · Paper page
10.1056/NEJMoa1615664 · DOI · Paper page
10.1016/j.jacc.2021.06.011 · DOI · Paper page
10.1016/j.jacc.2021.06.011 · DOI · Paper page
10.1016/j.jacl.2023.05.099 · DOI
10.1016/j.jacc.2021.06.011 · DOI · Paper page
10.1056/NEJMoa1812792 · DOI · Paper page
10.1016/j.jacc.2022.07.006 · DOI · Paper page
10.1161/CIR.0000000000000709 · DOI · Paper page
10.1161/CIR.0000000000000625 · DOI · Paper page
10.1161/CIR.0000000000000456 · DOI
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389.
10.1016/S0140-6736(10)61350-5 · DOI · Paper page
10.1016/j.jacc.2022.07.006 · DOI · Paper page
10.1056/NEJMoa1410489 · DOI · Paper page
10.1056/NEJMoa1615664 · DOI · Paper page
10.1056/NEJMoa1801174 · DOI · Paper page
10.1016/j.atherosclerosis.2018.06.002 · DOI · Paper page
10.1161/JAHA.118.011662 · DOI · Paper page
10.1016/j.jacc.2021.06.011 · DOI · Paper page
10.1016/j.jacc.2020.07.059 · DOI · Paper page
10.1161/circulationaha.114.012477 · DOI
Zheutlin AR, Handoo F, Luebbe S, et al. Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease. Eur Heart J. 2025;eha472.
10.1056/NEJMoa2109191 · DOI
10.1001/jamacardio.2021.3508 · DOI · Paper page
Stacey D, Legare F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;4:CD001431.
10.1161/CIR.0000000000000625 · DOI · Paper page
10.1161/CIRCULATIONAHA.123.067626 · DOI · Paper page
10.1016/S0140-6736(12)60367-5 · DOI · Paper page
10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
10.1161/CIR.0000000000000625 · DOI · Paper page
10.1161/CIR.0000000000000678 · DOI · Paper page
10.1161/ATVBAHA.120.315291 · DOI · Paper page
10.1056/NEJMoa0807646 · DOI · Paper page
10.1056/NEJMoa1107477 · DOI · Paper page
10.1161/CIR.0000000000000625 · DOI · Paper page
10.1161/CIR.0000000000000678 · DOI · Paper page
Urbut SM, Cho SMJ, Paruchuri K, et al. Dynamic importance of genomic and clinical risk for coronary artery disease over the life course. Circ Genom Precis Med. 2023;18:e004681.
10.1001/jama.2025.0584 · DOI
10.1093/eurheartj/ehad211 · DOI
10.1007/s40279-024-02115-z · DOI · Paper page
10.1210/clinem/dgaa673 · DOI · Paper page
10.1016/S0140-6736(12)60367-5 · DOI · Paper page
10.1016/j.jacc.2020.07.059 · DOI · Paper page
10.1056/NEJMoa0807646 · DOI · Paper page
10.1056/NEJMoa1600176 · DOI · Paper page
10.1001/jama.279.20.1615 · DOI · Paper page
10.1001/jamacardio.2021.3508 · DOI · Paper page
10.1001/jama.2016.13985 · DOI · Paper page
10.1056/NEJMoa2215024 · DOI · Paper page
10.1161/CIR.0000000000000678 · DOI · Paper page
10.1161/circulationaha.114.012477 · DOI
10.1161/01.cir.0000437738.63853.7a · DOI · Paper page
10.1161/CIR.0000000000000625 · DOI · Paper page
10.7326/M16-0946 · DOI
10.1016/S0140-6736(10)61350-5 · DOI · Paper page
10.1161/CIRCULATIONAHA.123.064168 · DOI
10.1161/circulationaha.116.022335 · DOI
10.1016/j.jacc.2016.03.520 · DOI · Paper page
10.1161/CIRCULATIONAHA.123.064168 · DOI
10.1056/NEJM199511163332001 · DOI · Paper page
10.1016/j.jacc.2016.03.520 · DOI · Paper page
10.1161/CIRCULATIONAHA.116.024541 · DOI
10.1056/NEJMoa1410489 · DOI · Paper page
10.1056/NEJMoa2215024 · DOI · Paper page
Kastelein JJ, Ginsberg HN, Langslet G, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36:2996–3003.
Raal F, Durst R, Bi R, et al. Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial. Circulation. 2023;354–362.
10.1001/jama.2016.13985 · DOI · Paper page
10.1016/S0140-6736(10)61350-5 · DOI · Paper page
10.1016/j.jacc.2021.06.011 · DOI · Paper page
10.1016/S0140-6736(14)61374-X · DOI
10.1056/NEJMoa2215024 · DOI · Paper page
10.1001/jama.2016.13985 · DOI · Paper page
10.1056/NEJM199511163332001 · DOI · Paper page
10.1161/CIRCULATIONAHA.117.027966 · DOI · Paper page
10.1136/bmj.a2423 · DOI
10.1016/j.jacc.2016.04.054 · DOI
10.1016/S0140-6736(10)61350-5 · DOI · Paper page
10.1161/CIRCULATIONAHA.122.063460 · DOI · Paper page
10.1056/NEJMoa1410489 · DOI · Paper page
10.1056/NEJMoa1812792 · DOI · Paper page
10.1001/jama.2016.13985 · DOI · Paper page
10.1056/NEJMoa0807646 · DOI · Paper page
10.1016/S0140-6736(10)61350-5 · DOI · Paper page
10.1056/NEJMoa2215024 · DOI · Paper page
10.1001/jama.2023.9696 · DOI · Paper page
10.1056/NEJMoa1615664 · DOI · Paper page
10.1056/NEJMoa1801174 · DOI · Paper page
10.1161/CIR.0000000000000625 · DOI · Paper page
10.1016/S0140-6736(10)61350-5 · DOI · Paper page
10.1001/jama.2016.13985 · DOI · Paper page
10.1056/NEJMoa1410489 · DOI · Paper page
10.1056/NEJMoa2215024 · DOI · Paper page
10.1056/NEJMoa1801174 · DOI · Paper page
10.1056/NEJMoa1615664 · DOI · Paper page
10.1161/CIRCULATIONAHA.122.061620 · DOI · Paper page
10.1161/CIR.0000000000000625 · DOI · Paper page
10.1161/JAHA.122.029216 · DOI · Paper page
10.1016/j.jacc.2020.07.059 · DOI · Paper page
10.1056/NEJMoa1801174 · DOI · Paper page
10.1177/2047487319864671 · DOI · Paper page
10.1016/j.jcmg.2019.02.005 · DOI · Paper page
10.1016/j.jcmg.2023.03.008 · DOI
10.1093/eurheartj/ehy217 · DOI · Paper page
10.1001/jama.2025.0584 · DOI
10.1016/j.jacc.2018.09.051 · DOI
10.1001/jamacardio.2016.5493 · DOI
10.1016/j.jcct.2023.10.001 · DOI
10.1148/radiol.15142062 · DOI · Paper page
10.1161/CIRCULATIONAHA.122.062746 · DOI · Paper page
10.1016/j.jacl.2020.12.005 · DOI
10.1056/NEJMoa2215024 · DOI · Paper page
Cannon CP, Blazing MA, Braunwald E. Ezetimibe plus a statin after acute coronary syndromes. N Engl J Med. 2015;373:1476–1477.
10.1056/NEJMoa1615664 · DOI · Paper page
10.1056/NEJMoa1801174 · DOI · Paper page
10.1161/circulationaha.116.027034 · DOI
10.1016/S0140-6736(10)61350-5 · DOI · Paper page
10.1161/CIRCIMAGING.120.011701 · DOI
10.1001/jamacardio.2024.5702 · DOI
10.1093/ehjci/jex239 · DOI · Paper page
Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2019;2019(11):CD006401.
10.1056/NEJMoa1816454 · DOI
10.1126/science.aaf7000 · DOI · Paper page
Schmieder RS, Krefting J, Ates S, et al. Clinical scores fail to sufficiently identify children with familial hypercholesterolemia. Eur J Prev Cardiol. 2025;zwaf301.
10.1001/jama.2019.4984 · DOI
10.1001/jamapediatrics.2021.2046 · DOI
10.1161/CIRCULATIONAHA.119.044795 · DOI
10.1016/j.jacc.2015.02.020 · DOI · Paper page
10.1056/NEJMoa2109191 · DOI
10.1001/jama.2023.8867 · DOI
10.1056/NEJMoa1602777 · DOI
10.1161/CIR.0000000000000625 · DOI · Paper page
10.1161/circulationaha.114.012477 · DOI
10.1016/j.jacc.2020.07.059 · DOI · Paper page
10.1056/NEJMoa2109191 · DOI
10.1161/circulationaha.116.022335 · DOI
10.1001/jamacardio.2021.3508 · DOI · Paper page
10.1001/jamanetworkopen.2021.36802 · DOI
10.1001/jamainternmed.2015.0289 · DOI · Paper page
10.1016/j.jacc.2016.05.084 · DOI
10.1161/CIR.0000000000001191 · DOI · Paper page
Martin SS, Aday AW, Allen NB, et al. 2025 Heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2025;25:e41–e660.
10.1161/CIR.0000000000000625 · DOI · Paper page
10.1161/CIR.0000000000000678 · DOI · Paper page
Dudum R, Huang Q, Yan XS, et al. Lipoprotein(a) levels in disaggregated racial and ethnic subgroups across atherosclerotic cardiovascular disease risk levels. J am Coll Cardiol Adv. 2024;3:100940.
10.1056/NEJMoa0706201 · DOI · Paper page
10.1016/S0140-6736(08)61240-4 · DOI · Paper page
10.1161/CIR.0000000000000625 · DOI · Paper page
10.1002/ejhf.247 · DOI · Paper page
10.1016/S0140-6736(11)60739-3 · DOI · Paper page
Tunnicliffe DJ, Palmer SC, Cashmore BA, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2023;2023:.
Igweonu-Nwakile EO, Ali S, Paul S, et al. A systematic review on the safety and efficacy of PCSK9 inhibitors in lowering cardiovascular risks in patients with chronic kidney disease. Cureus. 2022;14:e29140.
10.1016/j.jacc.2022.07.006 · DOI · Paper page
10.1001/jamainternmed.2013.3728 · DOI
10.1161/CIR.0000000000000456 · DOI
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Accessed August 24 2025. https://www.ncbi.nlm.nih.gov/sites/books/NBK586306/.
Sarkar S, Brown TT. Lipid disorders in people with HIV. Table 5. Interaction of antiretroviral therapy and statins. In: Feingold KR, Ahmed SF, Anawalt B, et al, editors. Endotext. MDText.com, Inc.; 2000. Accessed November 21, 2025. https://www.ncbi.nlm.nih.gov/books/NBK567198/table/lipid_hiv.T.interaction_of_antiretrovira.
10.1001/jamainternmed.2020.6084 · DOI · Paper page
10.1001/jamainternmed.2015.0289 · DOI · Paper page
10.1093/ajcn/56.2.320 · DOI · Paper page
10.1210/clinem/dgaa673 · DOI · Paper page
10.1056/NEJMoa1615664 · DOI · Paper page
10.1056/NEJMoa1801174 · DOI · Paper page
10.1056/NEJMoa2215024 · DOI · Paper page
10.1056/NEJMoa1812792 · DOI · Paper page
10.1161/CIRCULATIONAHA.123.067626 · DOI · Paper page
10.1016/j.jacc.2021.06.011 · DOI · Paper page
10.1016/j.jacl.2024.08.013 · DOI · Paper page

200 of 243 shown

Sorted by citations

2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 101
Self-citation
Epidemiology of cardiovascular–kidney–metabolic syndrome
Mavromatis, L. A., & Grams, M. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01078-w · Cited by 12
Global Burden of Elevated LDL-C
Collaborators, G. 2. L. C., Razo, C., DeCleene, N. K., Johnson, C. O., Stark, B. A., LeGrand, K. E., Aalruz, H., Abaraogu, U. O., ElHafeez, S. A., Abdelmasseh, M., et al. (2026) · JAMA · doi:10.1001/jama.2026.8628 · Cited by 8
Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial
Monguillon, V., Marston, N., Bohula, E. A., Park, J., Kuder, J., Murphy, S. A., Ferrari, G. M. D., Leiter, L. A., Nicolau, J. C., Ebenbichler, C. F., et al. (2026) · Circulation · doi:10.1161/circulationaha.126.080999 · Cited by 7
Self-citation
Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology
Khan, S. S., Bhave, N. M., Blumenthal, R. S., Coresh, J., Huang, X., Joseph, J. J., Khera, A., Ho, J. E., Lloyd‐Jones, D. M., Wang, C. C. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001447 · Cited by 11
Self-citation

See all 122

Authors: Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., Gianos, E., Gluckman, T. J., Gradney, K. F., Isiadinso, I., Lloyd-Jones, D. M., Marrs, J. C., Martin, S. S., McLain, K. H., Mehta, L. S., Mora, S., Mulugeta, W. M., Natarajan, P., Navar, A. M., Orringer, C. E., Polonsky, T. S., Reynolds, H. R., Saseen, J. J., Shapiro, M. D., Soffer, D. E., Tynes, S. A., Villavaso, C. D., Virani, S. S., Wilkins, J. T., Rohatgi, A., Kim, S. M., Alexander, K. P., Anderson, C., Benziger, C. P., Dixon, D. L., Duprez, D., Ferdinand, K. C., Goldberg, A. C., Joshi, P., Knowles, J. W., Lavie Jr, C. (. J., Linderbaum, J. A., McEvoy, J. W., Mehta, A., Merz, C. N. B., Nambi, V., Orkaby, A. R., Peña, Rosenson, R., Ruisinger, J., Sandner, S. E., Schott, S. L., Sperling, L. (., Stone, N. J., Toth, P., Ware, A. L., Whelton, S. P., & Young, J.
Affiliations: American Hospital Association (US)
Former ACC/AHA Joint Committee on Clinical Practice Guidelines member; current member during the writing effort.
American Geriatrics Society (US)
American Association of Cardiovascular and Pulmonary Rehabilitation representative.
ACC/AHA Task Force on Performance Measures liaison.
Patient representative.
Association of Black Cardiologists (US)
American Pharmacists Association (US)
American College of Preventive Medicine (US)
National Lipid Association (US)
American Society for Preventive Cardiology representative.
AHA/ACC Guidelines Staff Consultant.
Preventive Cardiovascular Nurses Association representative.
American Diabetes Association (US)
ORCID: Blumenthal, Roger S.
Gaudino, Mario
Johnson, Heather M.
Anderson, Timothy S.
Bittner, Vera A.
Blankstein, Ron
Brewer, LaPrincess C.
Cho, Leslie
de Ferranti, Sarah D.
Gianos, Eugenia
Gluckman, Ty J.
Isiadinso, Ijeoma
Marrs, Joel C.
Mehta, Laxmi S.
Mora, Samia
Mulugeta, Wudeneh M.
Natarajan, Pradeep
Orringer, Carl E.
Polonsky, Tamar S.
Reynolds, Harmony R.
Saseen, Joseph J.
Soffer, Daniel E.
Wilkins, John T.
Rohatgi, Anand
Alexander, Karen P.
Benziger, Catherine P.
Dixon, Dave L.
Ferdinand, Keith C.
Goldberg, Anne Carol
Knowles, Joshua W.
Linderbaum, Jane A.
McEvoy, John William
Nambi, Vijay
Orkaby, Ariela R.
Peña,, Jessica M.
Rosenson, Robert
Ruisinger, Janelle
Sandner, Sigrid E.
Schott, Stacey L.
Stone, Neil J.
Toth, Peter
Ware, Adam L.
Whelton, Seamus Paul
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2026-04-28
Volume: 153
Issue: 17
Pages: e1154-e1276
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/cir.0000000000001423
OpenAlex: W7135196205
Cited by: 122
References: 752
Citations by year: 2026: 122
FWCI: 769.87
Type: journal article
Language: en
Update notices: correction (2026-06-22)
correction (2026-09-08)
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
Keywords: dyslipidemia, dyslipidemia management, hypercholesterolemia, hypertriglyceridemia, serum cholesterol, lipid-lowering therapy, cardiovascular risk, lipid monitoring
MeSH terms: American Heart Association, Hypolipidemic Agents, Cardiology, Humans, United States, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks